menu search

VECT / Ironwood Pharmaceuticals to Acquire VectivBio for About $1 Billion

Ironwood Pharmaceuticals to Acquire VectivBio for About $1 Billion
Ironwood Pharmaceuticals is paying $17 a share for the Swiss biotech company. Read More
Posted: May 22 2023, 07:46
Author Name: Barrons
Views: 102834

VECT News  

Why Shares of VectivBio Holding Are Up Today

By The Motley Fool
May 22, 2023

Why Shares of VectivBio Holding Are Up Today

Ironwood Pharmaceuticals' buyout deal is worth $1 billion. The attraction was VectivBio's late-stage therapy, apraglutide. more_horizontal

VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion

By Investors Business Daily
May 22, 2023

VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion

Ironwood Pharmaceuticals said Monday it will buy VectivBio for $1 billion. The deal sent VECT stock flying, while IRWD stock skidded. more_horizontal

Ironwood Pharmaceuticals to Acquire VectivBio for About $1 Billion

By Barrons
May 22, 2023

Ironwood Pharmaceuticals to Acquire VectivBio for About $1 Billion

Ironwood Pharmaceuticals is paying $17 a share for the Swiss biotech company. more_horizontal

Ironwood Pharmaceuticals to acquire Swiss biotech VectivBio in deal valued at about $1 billion

By Market Watch
May 22, 2023

Ironwood Pharmaceuticals to acquire Swiss biotech VectivBio in deal valued at about $1 billion

Ironwood Pharmaceuticals Inc. IRWD, +2.45% said Monday it has agreed to acquire Swiss biotech VectivBio Holding AG VECT, +8.18% for $17 a share in cas more_horizontal

VectivBio: Swiss Company With Excellent Data, Upcoming Catalysts

By Seeking Alpha
April 17, 2023

VectivBio: Swiss Company With Excellent Data, Upcoming Catalysts

VectivBio: Swiss Company With Excellent Data, Upcoming Catalysts more_horizontal

VectivBio to Present at the 2022 Jefferies London Healthcare Conference

By GlobeNewsWire
November 9, 2022

VectivBio to Present at the 2022 Jefferies London Healthcare Conference

BASEL, Switzerland, Nov. 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical compan more_horizontal

VectivBio Holding AG (VECT) CEO Luca Santarelli on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
April 7, 2022

VectivBio Holding AG (VECT) CEO Luca Santarelli on Q4 2021 Results - Earnings Call Transcript

VectivBio Holding AG (VECT) CEO Luca Santarelli on Q4 2021 Results - Earnings Call Transcript more_horizontal

VectivBio to Present at the SVB Leerink 11th Annual Global Healthcare Conference

By GlobeNewsWire
February 8, 2022

VectivBio to Present at the SVB Leerink 11th Annual Global Healthcare Conference

BASEL, Switzerland, Feb. 08, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical compan more_horizontal


Search within

Pages Search Results: